Sun Pharma To Acquire Organon In $11.8 Billion All‑Cash Deal
India’s Sun Pharmaceutical Industries has agreed to acquire U.S.-listed Organon (NYSE: OGN) in an all‑cash transaction valuing the company at about $11.75–$11.8 billion, or $14 per share. The offer represents a premium to Organon’s prior close and implies an enterprise value that includes the target’s outstanding debt. The deal has been approved by both boards and is expected to close in early 2027, subject to regulatory clearances and Organon shareholder approval.
Strategic rationale and portfolio fit
Organon brings a global women’s health and established medicines portfolio of more than 70 products marketed in roughly 140 countries, including the U.S., Europe, China, Canada, and Brazil. For Sun Pharma, the transaction is framed as a way to scale its innovative and branded generics businesses, deepen exposure to women’s health, and gain an immediate position among the top players in biosimilars worldwide. Management commentary and third‑party analysis suggest the combined company could rank among the top 25 global pharma groups by revenue and potentially be a top‑three player in women’s health and a top‑10 biosimilars player.
Financial profile and funding
Organon generated around $6.2 billion in revenue in 2025 with roughly $1.9 billion in adjusted EBITDA and held several hundred million dollars in cash, according to reported figures. Sun Pharma has indicated that the purchase will be financed through a mix of existing cash and committed bank financing from a consortium of lenders, which introduces leverage considerations but preserves balance‑sheet flexibility. Sun and some analysts have highlighted potential revenue scale of about $12.4 billion for the combined business, though actual outcomes will depend on integration execution, market conditions, and product performance across key franchises.
Integration, timing, and key risks
The companies expect the transaction to close in early 2027, contingent on regulatory approvals in multiple jurisdictions and a favorable vote from Organon shareholders. Post‑close, Sun Pharma plans to integrate Organon as part of a broader push into women’s health, biosimilars, and established brands, which may involve portfolio optimization, cost initiatives, and potential R&D realignment. Investors tracking the story may focus on antitrust outcomes, leverage and interest‑rate dynamics, synergy delivery, and the durability of Organon’s women’s health and biosimilars revenues over time.
